Replies to post #108374 on Vivos Inc (RDGL)

[ogflee1]

Yes many variables/unknowns, as yet, thus Vivos was also approached to explore combination therapy.

Dr. Mike Korenko, Vivos CEO stated “I am pleased with the strong interest in IsoPet® from the practicing veterinary oncology community and are confident that our strategic plan is on course. There are some additional exciting initiatives that we plan on pursuing in the near future. At the conference, we initiated discussions with a company that is interested in working with us on a combination therapy that would be applicable for patients with more advanced disease. We would use IsoPet® to treat the primary tumors and would follow with their immunotherapy treatment to target cells that have metastasized. This combined therapy approach would broaden the application of IsoPet® for use on these very advanced cases and would be an option for animals that were considered terminal.”

[spaceship]

Are you a Doctor ? No worries Vivos Inc. has a few them they will figure it out. Go RDGL. See qualifications with link below provided.

https://www.radiogel.com/about-1/management-consultants/

[bdvest]

radiotherapy is widely used for treating cancer, there are no significant response differences among individuals.if there is way to deliver the radiogel with minimum invasive damage, it would work in controlling cancer, and improving life quality.